NSD3 and hematopoietic and lymphoid system neoplasm: In acute myeloid leukemia and acute lymphoblastic leukemia blood cancer, MS9715 could more effectively degrade NSD3, specifically inhibit the expression of c-Myc in cancer cells, and affect the growth of cells than BI-9321.